Earnings Call · Q2 FY2021·2021-08-05

Q2 21EPS -36.67%·Rev n/aQ1 21EPS +11.76%·Rev n/aQ4 20EPS -7.89%·Rev n/aQ3 20EPS +32.69%·Rev n/a⚠ consensus missing

Xeris Biopharma Holdings, Inc. XERS

Allison Wey — Senior Vice President of Investor Relations

Paul Edick — Chief Executive Officer (CEO)

Unknown

Steven Pieper — Chief Financial Officer (CFO)

−13.0%1d on move date−13.6% vs SPY3d−15.4%5d−17.5%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more XERS calls or request research access.

More XERS calls Browse calls Request research access